PAREXEL Releases New Report Defining Next Generation of CRO/Biopharma Industry Strategic Partnerships

PAREXEL International

, a leading global biopharmaceutical services organization, today released a new research report called Strategic Partnerships 2013 at the 22^nd Annual Partnerships in Clinical Trials Conference in Orlando, FL. The report is the first to explore the current outsourcing landscape and the value Strategic Partnerships provide to biopharmaceutical companies of all sizes. Strategic Partnerships are multi-year, highly-integrated engagements between biopharmaceutical companies and clinical research organizations (CROs). The report found that 85% of biopharmaceutical industry executives interviewed and who were engaged in Strategic Partnerships, believe that the relationship between their companies and CROs were positively impacted. Executives believe this more integrated approach to clinical development reduces their level of oversight, decreases fixed costs and provides them with access to capabilities not found internally.